Phase 0 Experimental Medicine Study of Direct Intratarget Pulmonary Microdosing of nlrp3/1 Inflammasome Inhibitor ads032: the Micro Study. A Protocol Paper
Clinical Research and Clinical Trials November 18, 2025 Tom M. Quinn, A Bruce, S Dickson et al.
Introduction High attrition in drug development remains a significant challenge for research and development organisations worldwide. Most novel drug compounds fail at an early stage, often without knowledge of target engagement or molecular efficacy at diseased tissue level. Phase 0 trials provide an opportunity to provide mechanistic data in a small number of patients at the earliest stage of...